Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-19-017654
Filing Date
2019-09-10
Accepted
2019-09-10 18:39:22
Documents
1
Period of Report
2019-09-06

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3887
  Complete submission text file 0001213900-19-017654.txt   5496
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Issuer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3031 TISCH WAY SUITE 505 SAN JOSE CA 95128
Business Address
Pearson Mark E. (Reporting) CIK: 0001486558 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-14778 | Film No.: 191086413